CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It has bacteriostatic activity against susceptible organisms.
| Metabolism | Primarily hepatic metabolism via CYP3A4 to active and inactive metabolites. About 10% excreted unchanged in urine; remainder as metabolites in bile and feces. |
| Excretion | Approximately 10-20% renal excretion as active clindamycin and its metabolites; 40-60% biliary/fecal excretion as inactive metabolites; primarily hepatic metabolism with enterohepatic circulation. |
| Half-life | Terminal elimination half-life is 2-4 hours in adults, 2.5-3.5 hours in children, and prolonged to 4-6 hours in severe hepatic impairment; clinically relevant for dosing interval (typically q6-8h). |
| Protein binding | 92-94% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-1.2 L/kg (adults), indicating extensive tissue distribution; penetrates bone, abscesses, and CSF (only with inflamed meninges). |
| Bioavailability | Oral: 90% (clindamycin hydrochloride capsules); IV: 100%; IM: 87-100% (clindamycin phosphate is a prodrug hydrolyzed to active clindamycin). |
| Onset of Action | IV: rapid, within minutes (peak serum concentrations achieved by end of infusion); IM: within 20-30 minutes; oral: 30-60 minutes for antibacterial effect. |
| Duration of Action | Serum levels above MIC for 6-8 hours after IV/IM dosing; bacteriostatic effect persists for 12 hours; clinical response may take 24-72 hours for symptom improvement. |
| Molecular Weight | 504.96 |
600 mg to 900 mg IV every 8 hours, or 900 mg to 1200 mg IV every 12 hours. Maximum 4800 mg/day.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for GFR >30 mL/min. For GFR 10-30 mL/min, administer usual dose every 8-12 hours. For GFR <10 mL/min, administer usual dose every 12-24 hours. Not significantly removed by hemodialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or prolong interval. Child-Pugh C: avoid or reduce dose by 75% with careful monitoring. |
| Pediatric use | Neonates: 15-20 mg/kg/day IV divided every 8-12 hours. Infants and children: 20-40 mg/kg/day IV divided every 6-8 hours. Maximum 4500 mg/day. |
| Geriatric use | No specific dose adjustment, but caution due to possible renal impairment. Use standard adult dosing with monitoring of renal function and dose interval adjustments as per renal function. |
| 1st trimester | Generally considered safe; no evidence of fetal harm. Crosses placenta but not associated with congenital anomalies. |
| 2nd trimester | Safe for use; similar to t1. Monitor for maternal gastrointestinal effects. |
| 3rd trimester | Safe; however, use near term may theoretically alter neonatal gut flora. Rare association with necrotizing enterocolitis in neonates if administered to mother shortly before delivery. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Crosses placenta readily; fetal serum levels reach ~30-50% of maternal serum levels. |
| Breastfeeding | Clindamycin is excreted into breast milk in small amounts. No adverse effects reported in breastfed infants, but may alter gut flora. Use caution with history of pseudomembranous colitis. |
| Lactation Rating | L2 (Possibly Compatible) |
| Teratogenic Risk | Clindamycin is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and there are no adequate and well-controlled studies in pregnant women. However, a meta-analysis of cohort studies suggests a possible increased risk of congenital anomalies (OR 1.37, 95% CI 1.04-1.81), particularly musculoskeletal defects, but confounding by indication cannot be excluded. Use only if clearly needed. |
| Fetal Monitoring | Monitor maternal renal and hepatic function. For prolonged use, periodic monitoring of CBC with differential and liver function tests. In neonates, observe for gastrointestinal disturbances if maternal use late in pregnancy or during lactation. |
| Fertility Effects | Animal studies show no impairment of fertility. No human data available. Clinical significance unknown. |
■ FDA Black Box Warning
Clindamycin can cause severe and sometimes fatal colitis, including pseudomembranous colitis, due to overgrowth of Clostridium difficile. This may occur during or after treatment.
| Common Effects | fluid replacement |
| Serious Effects |
Hypersensitivity to clindamycin, lincomycin, or any componentHistory of pseudomembranous colitisKnown inflammatory bowel disease (e.g., Crohn's, ulcerative colitis) - relative contraindication, but sometimes considered absolute depending on severity
| Precautions | Clostridium difficile-associated diarrhea (CDAD) can occur; monitor for diarrhea. May cause severe hypersensitivity reactions including anaphylaxis. Prolonged use may result in superinfection. Not recommended for meningitis due to poor CNS penetration. |
| Food/Dietary | No significant food interactions. Administer without regard to meals. |
| Clinical Pearls | Clindamycin phosphate in 0.9% sodium chloride is used intravenously. Monitor for pseudomembranous colitis due to Clostridioides difficile. Avoid rapid infusion to minimize hypotension. Check renal function as dosage adjustment may be needed in severe impairment. Use with caution in patients with gastrointestinal disease. |
| Patient Advice | This medication is given intravenously to treat bacterial infections. · Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately. · Contact your healthcare provider if you develop severe or persistent diarrhea, as this may indicate a serious bowel condition. · Complete the full course of therapy even if you feel better. · Inform your doctor if you have a history of colitis or kidney disease. |
Loading safety data…